Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques
Mireille Laforge, … , Anna Senik, Jérôme Estaquier
Mireille Laforge, … , Anna Senik, Jérôme Estaquier
Published April 2, 2018; First published March 19, 2018
Citation Information: J Clin Invest. 2018;128(4):1627-1640. https://doi.org/10.1172/JCI95127.
View: Text | PDF
Categories: Research Article AIDS/HIV Immunology

The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques

  • Text
  • PDF
Abstract

Apoptosis has been proposed as a key mechanism responsible for CD4+ T cell depletion and immune dysfunction during HIV infection. We demonstrated that Q-VD-OPH, a caspase inhibitor, inhibits spontaneous and activation-induced death of T cells from SIV-infected rhesus macaques (RMs). When administered during the acute phase of infection, Q-VD-OPH was associated with (a) reduced levels of T cell death, (b) preservation of CD4+/CD8+ T cell ratio in lymphoid organs and in the gut, (c) maintenance of memory CD4+ T cells, and (d) increased specific CD4+ T cell response associated with the expression of cytotoxic molecules. Although therapy was limited to the acute phase of infection, Q-VD-OPH–treated RMs showed lower levels of both viral load and cell-associated SIV DNA as compared with control SIV-infected RMs throughout the chronic phase of infection, and prevented the development of AIDS. Overall, our data demonstrate that Q-VD-OPH injection in SIV-infected RMs may represent an adjunctive therapeutic agent to control HIV infection and delaying disease progression to AIDS.

Authors

Mireille Laforge, Ricardo Silvestre, Vasco Rodrigues, Julie Garibal, Laure Campillo-Gimenez, Shahul Mouhamad, Valérie Monceaux, Marie-Christine Cumont, Henintsoa Rabezanahary, Alain Pruvost, Anabela Cordeiro-da-Silva, Bruno Hurtrel, Guido Silvestri, Anna Senik, Jérôme Estaquier

×

Figure 7

Expression of cytolytic molecules in CD4+ T cells of SIV-infected RMs.

Options: View larger image (or click on image) Download as PowerPoint
Expression of cytolytic molecules in CD4+ T cells of SIV-infected RMs.
(...
(A) Flow cytometric analyses of perforin, granzyme B, and granulysin expressions in CD4+ T cells from peripheral blood of 1 representative healthy RM (naive) and 1 SIV-infected RM treated with Q-VD-OPH (SIV+Q-VD). (B) Histogram shows the percentage of CD4+ T cells expressing perforin, granzyme B, and granulysin at day 120 (each dot plot represents 1 individual). (C) Percentages and (D) cell numbers of CD4+ T cells expressing TIA1 in either untreated (placebo, n = 6) or Q-VD-OPH–treated RMs (n = 6) on days 0, 7, 14, 21, 30, 60, 120, 180, and 360 after infection. Statistical differences were assessed using the Mann-Whitney U test (*0.01 < P < 0.05; **0.001 < P < 0.01; ***P < 0.001). In B–D, values above data represent P values. Prism was used to present the results in box-and-whisker plots showing the minimum and maximum of all the data.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts